Business Description
Akari Therapeutics PLC
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
CLAB.GermanyAKTX.USA IPO Date
2012-12-07Description
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.73 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 35.9 | |||||
| 3-Year EPS without NRI Growth Rate | 26 | |||||
| 3-Year FCF Growth Rate | 33.3 | |||||
| 3-Year Book Growth Rate | -15.9 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.72 | |||||
| 9-Day RSI | 32.87 | |||||
| 14-Day RSI | 31.42 | |||||
| 6-1 Month Momentum % | -38.59 | |||||
| 12-1 Month Momentum % | -69.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.73 | |||||
| Quick Ratio | 3.73 | |||||
| Cash Ratio | 2.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -44.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -221.95 | |||||
| ROA % | -145.87 | |||||
| ROIC % | -6616.91 | |||||
| ROC (Joel Greenblatt) % | -11791.67 | |||||
| ROCE % | -225.63 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.79 | |||||
| Price-to-Tangible-Book | 1.79 | |||||
| EV-to-EBIT | -0.57 | |||||
| EV-to-EBITDA | -0.57 | |||||
| EV-to-FCF | -0.52 | |||||
| Price-to-Net-Current-Asset-Value | 1.79 | |||||
| Price-to-Net-Cash | 2.78 | |||||
| Earnings Yield (Greenblatt) % | -175.44 |
How Akari Therapeutics PLC (AKTX) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AKTX
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.349 | ||
| Beta | 1.16 | ||
| Volatility % | 64.08 | ||
| 14-Day RSI | 31.42 | ||
| 14-Day ATR ($) | 0.042285 | ||
| 20-Day SMA ($) | 0.28775 | ||
| 12-1 Month Momentum % | -69.54 | ||
| 52-Week Range ($) | 0.22 - 1.61 | ||
| Shares Outstanding (Mil) | 74.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Akari Therapeutics PLC Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Akari Therapeutics PLC Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Akari Therapeutics PLC Frequently Asked Questions
What is Akari Therapeutics PLC(AKTX)'s stock price today?
The current price of AKTX is $0.25. The 52 week high of AKTX is $1.61 and 52 week low is $0.22.
When is next earnings date of Akari Therapeutics PLC(AKTX)?
The next earnings date of Akari Therapeutics PLC(AKTX) is 2023-05-16 Est..
Does Akari Therapeutics PLC(AKTX) pay dividends? If so, how much?
Akari Therapeutics PLC(AKTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
